Connect with us

Business

Gilead to acquire CymaBay for $32.50/share in cash (NASDAQ:GILD)

[ad_1]

Gilead Sciences (NASDAQ:GILD) has agreed to acquire CymaBay Therapeutics (NASDAQ:CBAY) for a total equity value of $4.3B.

Pursuant to the terms of the merger agreement, a Gilead (GILD) subsidiary will launch a tender offer to acquire all outstanding shares

[ad_2]

Source link